Drug intelligence / Profile preview

miR-10a inhibitor

Development stage
Preclinical
Lead developer
UT Health San Antonio
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

miR-10a inhibitor is a synthetic oligonucleotide designed to bind and neutralize microRNA-10a (miR-10a). In the context of lung cancer research, miR-10a has been identified as a potential regulator of cell viability and growth, specifically targeting the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). Preclinical studies presented at the AACR 2012 meeting demonstrated that inhibition of miR-10a increases cell viability in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines, suggesting that miR-10a may function as a tumor suppressor. Despite the observation that its inhibition promotes growth in these models, researchers have explored miR-10a modulation as a potential therapeutic strategy for treating lung malignancies.

Other names
microRNA-10a inhibitormicroRNA10a inhibitormicroRNA 10a inhibitorantagomir-10aantagomir10aantagomir 10aanti-miR-10aanti-miR10aanti-miR 10a

Beyond the preview

Go deeper on miR-10a inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-10a inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call